New Approach Entails a Defined Antibody Combination Targeting Multiple Epitopes and Mechanisms of Viral Evasion.
Revenue outlook is positive for the fourth quarter.
The purpose is to reduce the ongoing debt obligations.
EVQLV can filter antibody candidates with a higher probability of success against the SARS-CoV-2 Coronavirus.
IPA to develop innovative vaccines and coronavirus-neutralizing antibodies against SARS-CoV-2.
The BioXp 3200 will reduce the turnaround time for cloning activities in discovery and manufacturing projects